Poxel Advances Global Strategy with Key Patent for Imeglimin in China Expanding Innovative Treatments for Chronic Metabolic Diseases Poxel, a clinical-stage biopharmaceutical company focused on developing cutting-edge treatments for chronic diseases with metabolic origins, has reached a significant milestone in…
WHO Welcomes Gaza Ceasefire but Highlights Immense Health Challenges Ahead The World Health Organization (WHO) has welcomed the Gaza ceasefire and the associated hostage and prisoner release deal, bringing a glimmer of hope to millions whose lives have been devastated…
The World Health Organization (WHO) has welcomed the recently brokered ceasefire in Gaza, along with the hostage and prisoner release agreement. This development offers a glimmer of hope for millions of people whose lives have been devastated by the ongoing…
Walgreens Steps Up Amid the ‘Quad-Demic’: Vaccines, Testing, Treatments, and Support The term “tripledemic” gained traction not too long ago to describe the simultaneous surges of flu, COVID-19, and respiratory syncytial virus (RSV). However, in 2025, a new term has…
Bayer’s Pharma Growth Strategy Advances as Pipeline Progresses At the 43rd J.P. Morgan Healthcare Conference in San Francisco, Bayer AG revealed significant advancements in its pharmaceutical growth strategy, announcing multiple filings for key drugs such as darolutamide, finerenone, acoramidis, and…
Blueprint Medicines Corporation recently unveiled its 2025 corporate outlook and strategic vision for sustained growth, leveraging its established research, development, and commercial expertise. According to Kate Haviland, Chief Executive Officer of Blueprint Medicines, the company enters 2025 stronger than ever,…
Osimertinib: A Benchmark in Targeted Therapy Osimertinib The European Commission has granted approval for the combination of RYBREVANT® (amivantamab) and LAZCLUZE® (lazertinib) for the first-line treatment of adult patients with advanced non-small cell lung cancer (NSCLC) who harbor EGFR exon…
Formulation Results from the IRAKLIA Phase 3 Study Demonstrate Promise for Subcutaneous Sarclisa in Multiple Myeloma The Formulation IRAKLIA Phase 3 study has presented encouraging results for the investigational subcutaneous (SC) formulation of Sarclisa, administered through an on-body delivery system…
The Role of G6PD Testing in Malaria Treatment On December 18, 2024, the World Health Organization (WHO) achieved a groundbreaking milestone by prequalifying the first diagnostic test for glucose-6-phosphate dehydrogenase (G6PD) deficiency. This move aims to enhance the safe delivery…
A Cautiously Optimistic Outlook for Biopharma in 2025 The biopharma sector is poised for a cautious but optimistic rebound in 2025, driven by renewed investment, the growing influence of artificial intelligence (AI), and a continued focus on late-stage assets and…
Biopharma Leaders M&A Didn’t Deliver as Expected in 2024: Biopharma Turns to JPMorgan Healthcare Conference for Optimism Biopharma Leaders the much-anticipated mergers and acquisitions (M&A) wave that the biopharma industry hoped would materialize in 2024 did not arrive as expected,…
Propranolol Reduces Tremors in Parkinson’s Disease: Insights into the Role of Stress and the Brain Parkinson’s disease is a progressive neurodegenerative disorder that affects movement, often leading to symptoms such as tremors, stiffness, and slowness of movement. Tremors, in particular,…